Patients suffering from Type 1 Diabetes rely on the exogenous supply of insulin. Cell replacement therapy employing cadaveric islets cells has demonstrated a proof of principle for a practical cure, rendering patients insulin independent for prolonged periods of time. However, challenges remain before this innovative therapy can be widely accessed by diabetic patients. Availability of cadaveric donor islets is limited, necessitating the generation of an abundant source of insulin-producing pancreatic beta cells. Immunological rejection of the allogeneic transplant and recurring autoreactivity contribute to eventual graft failure in all transplant recipients. In the current chapter, we summarize past and current efforts to generate functional beta cells from pluripotent stem cells and highlight current knowledge on graft immune interactions. We further discuss remaining challenges of current cell replacement efforts and highlight potentially innovative approaches to aid current strategies.
Efficient and reproducible generation of functional stem cell-derived β cells (sBC) remains a major challenge for basic research and cell replacement therapy, partly due to incomplete understanding of endocrine induction during differentiation and challenges with clinical scale-up. Here, we dissect the individual contributions of commonly used endocrine differentiation factors on pancreatic progenitor maintenance, endocrine commitment, and hormone subset generation in a scalable 3D differentiation system. We demonstrated that starting pluripotent stem cell cluster size is a critical determinant for downstream sBC generation. We also verify that a commonly employed combination of endocrine induction molecules efficiently drives endocrine lineage commitment but yields limited β-cell generation. Detailed analysis of the effects of individual endocrine induction molecules revealed distinct effects: EGF or KGF preserved NKX6.1+ progenitors without induction of endocrine differentiation; Notch or BMP inhibition robustly induced endocrine marker expression but concurrently reduced NKX6.1 expression, resulting in predominant generation of glucagon-expressing cells; retinoic acid, thyroid hormone (T3), or TGFβ inhibition maintained high NKX6.1 levels while also promoting efficient insulin+ endocrine differentiation. These findings indicate NKX6.1 protein maintenance as a key determinant of human β-cell generation and show that endocrine differentiation factors exert divergent effects on lineage progression.